0 Datasets
0 Files
Get instant academic access to this publication’s datasets.
Yes. After verification, you can browse and download datasets at no cost. Some premium assets may require author approval.
Files are stored on encrypted storage. Access is restricted to verified users and all downloads are logged.
Yes, message the author after sign-up to request supplementary files or replication code.
Join 50,000+ researchers worldwide. Get instant access to peer-reviewed datasets, advanced analytics, and global collaboration tools.
✓ Immediate verification • ✓ Free institutional access • ✓ Global collaborationJoin our academic network to download verified datasets and collaborate with researchers worldwide.
Get Free Accessfollow up, n6, 46% experienced rash; n6, 46% diarrhea; n3, 23% required phosphate supplement.Delayed AEs included a case of hidradenitis.Among the 4 female pts, 3 (75%) experienced ovarian toxicity.The 3 pts who underwent dose reductions did so due to rash, diarrhea and fatigue; and diarrhea, respectively.All pts tolerated the reduced dose of 100 mg BID.At the most recent follow-up, 8 pts (62%) had reported improved pain from baseline. 2 out of 5 pts (40%) with intrabdominal tumors had RECIST 1.1 partial response.Conclusions: Nirogacestat was well tolerated, with management of AEs at first month associated with dose interruptions but infrequent dose reductions.Our findings support the recommended starting dose of 150 mg twice daily (BID) in real-world experience.
Emanuela Palmerini, S. Veltkamp, H. Gelderblom, Javier Martín‐Broto, A. Sebio García, M. Van de Sande, Gabriel Tinoco, Elyse Seltzer, Matthew Davies, Jean Yves Blay (2025). 151TiP TANGENT: A phase III, global, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of emactuzumab in patients with tenosynovial giant cell tumor. , 10, DOI: https://doi.org/10.1016/j.esmoop.2025.104464.
Datasets shared by verified academics with rich metadata and previews.
Authors choose access levels; downloads are logged for transparency.
Students and faculty get instant access after verification.
Type
Article
Year
2025
Authors
10
Datasets
0
Total Files
0
Language
en
DOI
https://doi.org/10.1016/j.esmoop.2025.104464
Access datasets from 50,000+ researchers worldwide with institutional verification.
Get Free Access
